Citable filing context
COO's research view summarizes recent SEC filing context, starting with earnings from Jun 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Jun 4, 2026 | earnings | Cooper Companies reported Q2 2026 revenue of $1.082 billion and a $271.6 million litigation-related charge. |
| May 4, 2026 | management_change | The Cooper Companies, Inc. appointed Paul Keel to its Board of Directors, effective July 1, 2026. |
| Apr 8, 2026 | other | The Cooper Companies, Inc. held its 2026 Annual Meeting, electing directors and ratifying KPMG LLP. |
| Jun 4, 2026 | Guidance: coopersurgical_revenue | 1402.00 to 1414.00 |
| Jun 4, 2026 | Guidance: coopervision_revenue | 2883.00 to 2908.00 |
| Jun 4, 2026 | Guidance: non_gaap_diluted_eps | 4.58 to 4.66 |
| Jun 5, 2026 | mda_quarterly | CooperVision net sales grew 8% for the first six months of fiscal 2026, driven by silicone hydrogel products including MyDay and Biofinity. Growth was strongest in EMEA (16%) and the Americas (7%), though offset by softness in Japan. CooperSurgical net sales increased 8% in the second quarter, fueled by fertility consumables and genetic testing, despite declining Paragard contraceptive revenue. Consolidated gross margin remained flat at 68%. However, CooperSurgical reported a significant operating loss due to a $271.6 million litigation expense related to the LifeGlobal embryo culture media recall, involving over 1,500 claimants. Additional financial risks include a UK payroll tax dispute regarding the Sauflon Group acquisition with a potential loss of up to £71.7 million and ongoing compliance with EU Medical Devices Regulations. Working capital decreased to $495.1 million, primarily due to increased short-term debt, but the company maintains $1.38 billion in available revolving credit. The company continues to prioritize the shift toward single-use contact lens modalities and the expansion of MiSight for myopia management. Interest expenses decreased due to lower average debt balances and rates, while the company repurchased $105.6 million in common stock during the first half of the year. |
| Mar 6, 2026 | mda_quarterly | CooperVision net sales grew 8% to $695.1 million, driven by silicone hydrogel products including MyDay and Biofinity, with strong gains in EMEA (15%) and the Americas (7%) offsetting a 4% decline in Asia Pacific. Growth was bolstered by MiSight’s myopia management technology and a global market shift toward single-use modalities. CooperSurgical net sales increased 3% to $329 million, led by fertility consumables, though partially offset by declining Paragard contraceptive IUD revenue. Consolidated gross margin remained flat at 68%, while operating income rose 17% to $212.8 million. Financial liquidity remains stable with $260.9 million in operating cash flow and $1.37 billion available under the 2024 Revolving Credit Agreement. The company repurchased $92.5 million in common stock during the quarter. Key risks include global macroeconomic instability, EU Medical Devices Regulation (MDR) compliance, and foreign exchange volatility, which provided a $28.1 million tailwind this period. Additionally, a UK tax dispute regarding the Sauflon Group acquisition presents a potential liability of up to £71.7 million plus interest. |
Source: SEC EDGAR filing text and events; period Jun 4, 2026; filed Jun 4, 2026.
COO company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.